Followers | 261 |
Posts | 51308 |
Boards Moderated | 17 |
Alias Born | 08/29/2007 |
![](https://investorshub.advfn.com/uicon/108458.png?cb=1482855649)
Sunday, March 31, 2024 2:16:33 PM
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent TAK News
- Takeda kündigt neue Besetzung der Direktorenposten an • Business Wire • 06/26/2024 11:43:00 PM
- Takeda annonce de nouvelles nominations de directeurs • Business Wire • 06/26/2024 11:25:00 PM
- Takeda Announces New Assignments of Directors • Business Wire • 06/26/2024 07:05:00 AM
- 取締役分掌等の決定について • Business Wire • 06/26/2024 07:05:00 AM
- Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies • Business Wire • 06/24/2024 07:00:00 AM
- Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia • Business Wire • 06/23/2024 02:30:00 AM
- HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda • GlobeNewswire Inc. • 06/21/2024 08:00:00 PM
- Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer • Business Wire • 06/21/2024 08:00:00 PM
- HyQviaMD de Takeda approuvé comme traitement substitutif chez les enfants de 2 ans ou plus atteints d'immunodéficience humorale primaire ou secondaire • PR Newswire (Canada) • 06/21/2024 12:00:00 PM
- Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older • PR Newswire (Canada) • 06/21/2024 12:00:00 PM
- 武田薬品、PNS年次総会にて慢性炎症性脱髄性多発神経炎(CIDP)患者を対象としたHYQVIA®の第3相ADVANCE-CIDP3臨床試験の長期データを発表 • Business Wire • 06/20/2024 02:36:00 PM
- Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (P • Business Wire • 06/19/2024 05:25:00 PM
- Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung • Business Wire • 06/19/2024 08:24:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/17/2024 10:46:29 AM
- Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome • Business Wire • 06/17/2024 10:45:00 AM
- Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI) • Business Wire • 06/14/2024 12:00:00 PM
- Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts • Business Wire • 06/11/2024 12:00:00 PM
- Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo • Business Wire • 06/03/2024 10:45:00 AM
- Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma • Business Wire • 06/01/2024 12:00:00 PM
- Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP) • Business Wire • 05/31/2024 01:57:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/21/2024 10:02:25 AM
- Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection • PR Newswire (Canada) • 05/16/2024 12:02:00 PM
- Takeda Canada Inc. conclut une lettre d'intention avec l'Alliance pancanadienne pharmaceutique (APP) concernant LIVTENCITY® (maribavir) pour le traitement des adultes greffés atteints d'une infection à cytomégalovirus (CMV) • PR Newswire (Canada) • 05/16/2024 12:02:00 PM
- Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting • Business Wire • 05/14/2024 12:00:00 PM
- Takeda annonce ses résultats pour l’exercice 2023 et ses perspectives pour l’exercice 2024, confirmant son engagement en faveur du développement d’un portefeuille de produits à un stade avancé et de l’augmentation de la marge bénéficiaire... • Business Wire • 05/10/2024 11:03:00 AM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM